Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PhotonPharma Closes $2.5 Million Seed Funding for Ovarian Cancer Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News

PhotonPharma Closes $2.5 Million Seed Funding for Ovarian Cancer Therapy

Marks a significant milestone for PhotonPharma as the company prepares to initiate a Phase I clinical trial for Innocell.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

PhotonPharma, a biopharmaceutical company focused on developing innovative cancer treatments, has successfully secured $2.5 million in seed funding. This investment will fuel the advancement of Innocell, a promising therapy designed to target advanced ovarian cancer.
 
The funding round marks a significant milestone for PhotonPharma as the company prepares to initiate a Phase I clinical trial for Innocell. The trial is expected to enroll its first patient in the fourth quarter of 2024, providing valuable data on the safety and efficacy of the therapy.
 
“This funding is a significant milestone for PhotonPharma and marks a pivotal moment in our mission to advance breakthrough therapies for cancer therapies,” said Dr. Terry Opgenorth, Chairman of the Board of Directors of PhotonPharma. “We are excited to move forward with our clinical trials and are grateful for the support of our investors, whose confidence will help drive the development of our technology platform forward.”
 
PhotonPharma will be presenting its progress and development plans at the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference. This event will offer an opportunity for investors and industry partners to learn more about the company’s innovative approach and the potential impact of Innocell on ovarian cancer treatment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics